Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Ranexa Prescribers: Heart Failure Specialists (US)(?)

Council Members in this Study Group: 20

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Howard Weintraub, MD
Clinical Director
New York University Medical Center

Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub has written textbook chapters on evaluation...

Hossein Ardehali, MD, PhD, Assistant Professor, Feinberg School of Medicine, Northwestern UniversityHossein Ardehali, MD, PhD
Assistant Professor
Feinberg School of Medicine, Northwestern University

Hossein Ardehali, MD, PhD, is an Assistant Professor of Medicine at Feinberg Cardiovascular Institute in Illinois. His specialties include lipid metabolism, preventive cardiology, electrophysiology and heart failure. Dr. Ardehali's basic science research interest is in the areas of reperfusion injury...

Samuel Butman, MD, Interventional Cardiologist, Verde Valley Heart LLCSamuel Butman, MD
Interventional Cardiologist
Verde Valley Heart LLC

Samuel Butman, MD, is an Interventional Cardiologist at Verde Valley Medical Center. Dr. Butman is also a Clinical Associate Professor of Medicine at University Medical Center in Tucson, Arizona. He has also served as the Director of Cardiology Interventional Fellows Program and Director of Cardiac...

Bernard Chaitman, MD, Professor and Director, SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINEBernard Chaitman, MD
Professor and Director
SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE

Bernard Chaitman, MD, is Professor of Internal Medicine and Director of Cardiovascular Research at the St. Louis University School of Medicine in Missouri. He is also the Director of the Core ECG Laboratory. Dr. Chaitman has research interests in anti-anginal drug therapies, including Ranolazine, Nicorandil,...

Jesse Sethi
Cardiologist/ Electrophysiologist
Cardiac Solutions

Jesse Sethi, MD, FACC, is a Cardiologist and Electrophysiologist at Cardiac Solutions, a private practice in Arizona. Dr. Sethi has expertise in electrophysiology procedures such as pacemakers, defibrillators (ICDs), biventricular ICDs, cardiac resynchronization therapy (CRT), atrial and ventricular...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

It is well known that the addition of thiazide diuretic to ACEI or ARB treatment adds about 10 mm Hg reduction on top of the 10 mm Hg reduction provided by the ACEI or ARB agent.  It is expected that blocking renin in the renin angiotensin system with Tekturna would provide a similar result.

TRITON-TIMI 38 study of 13,608 patients with ACS compared prasugrel against clopidogrel, combined with aspirin.  Prasugrel reduced the combined rate of CV death, MI or stroke (12.1% for clopidogrel vs. 9.9% for prasugrel). The benefit came at a cost of increased serious bleeding (1.4%, vs....

By Samuel Butman, MD, Interventional Cardiologist, Verde Valley Heart LLC
Analysis of: Schering releases ENHANCE data today | www.tradingmarkets.com

The reality that the actual details of the ENHANCE have not been circulated and that alternate explanations or caveats may be raised is probably unimportant.   The bottom line carries the day and the bottom line is that the trial's title, ENHANCE, was not achieved by the addition of VYTORIN when...

Analysis of: Schering releases ENHANCE data today | www.tradingmarkets.com

Physicians have several possible conclusions that can be taken; These include: - the trial is flawed - the selection of patients with much less CIMT than previous trials such as ASAP and ARBITER flaws the study -  the failure to meet the trial endpoint is only a surrogate and clinical trial data...

This is great news for Canada.  This is the first new drug approved for the treatment of acute heart failure since 1989, when milrinone was approved.  Nesiritide was approved in the United States in 2001.  Since then, it has proven to be of great benefit in patients with acute heart failure,...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Academic Institution*
  • Government/Military Hospital or Clinic
  • Non-Academic Community Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Owner
  • Partner
  • Physician - Department Chair
  • Physician - Division Head
  • Researcher

GLG's 850+ Clients Include:

Fortune 500®  companies
40 of the leading 50  global mutual funds
15 of the leading 20  global banks
8 of the leading 10  global private equity firms
5 of the top 10  AmLaw firms

Analytics


Generated at 2009-01-08T19:00:17.880